Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study-Reference-Cited by-同舟云学术

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study

Published:2017-08-02 Issue:1 Volume:17 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Martirosov Dmitriy M.,Bidell Monique R.,Pai Manjunath P.,Scheetz Marc H.,Rosenkranz Susan L.,Faragon Corey,Malik M.,Mendes R. E.,Jones R. N.,McNutt Louise-Anne,Lodise Thomas P.

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-017-2609-0.pdf

Reference14 articles.

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.

2. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus Aureus in a UK hospital. J Antimicrob Chemother. 2001;47(4):399–403.

3. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus Aureus. Clin Infect Dis. 2004;38:448–51.